Eve joined Medicines Discovery Catapult in January 2022 following her PhD in Biomedical Science at the University of Sheffield.
There she focused on research into the mechanisms of chronic neuropathic pain and the use of novel, retargeted botulinum toxins to prevent or reverse it. As part of a MRC iCASE studentship, she gained experience of both academic research at Sheffield and translational research within industry at Eli Lilly. In her role within the cell models team at MDC, she applies her expertise of functional neuronal assays to complex iPSC-derived CNS models.
